Entera Bio Ltd. — Form 10-Q
Filed August 7, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Miranda Toledano (CEO) and Dana Yaacov-Garbeli (CFO) certified the Q2 2026 10-Q filing on August 7, 2026, attesting that financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud were disclosed.
Why this rating
Routine SOX certification exhibit; absence of control weaknesses is baseline good governance but not a material business event for a $85M biotech company.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.